A Study of JNJ-40346527 in Patients With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy
The purpose of this study is to evaluate the safety, tolerability, and efficacy of JNJ-40346527 200 mg/day (100 mg twice daily) for 12 weeks, compared with placebo, in patients with active rheumatoid arthritis (RA) despite disease-modifying antirheumatic drug (DMARD) therapy.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
|Official Title:||A Phase 2a, Randomized, Multicenter, Double-blind, Placebo-controlled, Parallel-group Study of JNJ-40346527 in Subjects With Active Rheumatoid Arthritis Despite Disease-modifying Antirheumatic Drug Therapy|
- Change from baseline in the Disease Activity Score (DAS28), using C-reactive protein (CRP) [ Time Frame: Week 12 ] [ Designated as safety issue: No ]The DAS28 is a statistically derived index combining tender joints (28 joints), swollen joints (28 joints), CRP, and an overall assessment of disease activity.
- ACR 20 response [ Time Frame: Week 12 ] [ Designated as safety issue: No ]ACR 20 (American College of Rheumatology) response is a 20% improvement in rheumatoid arthritis (RA) symptoms.
- DAS28 (using CRP) response [ Time Frame: Week 12 ] [ Designated as safety issue: No ]DAS28 response is the improvement from baseline and is rated as "No response," Moderate response," or "Good response."
|Study Start Date:||July 2012|
|Study Completion Date:||April 2013|
|Primary Completion Date:||April 2013 (Final data collection date for primary outcome measure)|
Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.
|Placebo Comparator: Placebo||
Form=capsule; route=oral use; twice daily.
This is a randomized (treatment assigned by chance, like flipping a coin), multicenter, double-blind (neither physician nor patient will know the treatment the patient receives), parallel-group (each group of patients will be treated at the same time) study. JNJ-40346527 will be compared to a placebo, which is an inactive substance used to test whether a drug has a real effect. Patients will receive study medication for 12 weeks and will continue their permitted, stable DMARD therapy (methotrexate [MTX], sulfasalazine [SSZ], and/or hydroxychloroquine [HCQ]) through Week 12. A follow-up visit will occur 4 weeks after dosing is complete. The maximum length of patient participation will be 22 weeks, including a 6-week screening period. Other study visits will occur during the study, and patient safety will be monitored.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01597739
Hide Study Locations
|Buenos Aires, Argentina|
|San Juan, Argentina|
|San Miguel De Tucuman, Argentina|
|Veliko Turnovo, Bulgaria|
|Praha 4, Czech Republic|
|Praha 5, Czech Republic|
|Slany, Czech Republic|
|Korea, Republic of|
|Gwangju, Korea, Republic of|
|Seoul, Korea, Republic of|
|Suwon, Korea, Republic of|
|Kazan, Russian Federation|
|Moscow, Russian Federation|
|Novosibirsk, Russian Federation|
|Petrozavodsk, Russian Federation|
|Saint Petersburg, Russian Federation|
|Ulyanovsk, Russian Federation|
|Yaroslavl, Russian Federation|
|Study Director:||Janssen Research & Development, LLC Clinical Trial||Janssen Research & Development, LLC|